A Long-term Follow-up Study of Patients With MPS IIIA Treated With ABO-102

Phase 3

• Conditions: Mucopolysaccharidosis III-A
• Interventions: Other: No Investigational Product; Drug: Adjuvant Immunosuppression (IS) Therapy

• Registration Number: NCT04360265
• Lead Sponsor: Ultragenyx Pharmaceutical Inc

Brief Summary

The main objective of this study is to evaluate the long-term safety and tolerability of ABO-102 in participants with MPS IIIA.

Detailed Description

This is a multicenter, long-term follow-up study of patients with MPS IIIA who have completed a prior clinical trial involving the administration of ABO-102 (NCT02716246 and NCT04088734). No investigational product will be provided. At approved sites immunosuppression (IS) therapy may be administered to selected participants. The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IS therapy. Not all participants may receive IS therapy.

This study was previously posted by Abeona Therapeutics, Inc and was transferred to Ultragenyx in August 2022.

Study Timeline

• Study First Submitted: 2020-04-20
• Study First Submitted QC: 2020-04-21
• Study First Posted: 2020-04-24
• Study Start: 2020-09-28
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-01
• Last Update Posted: 2024-08-02
• Primary Completion: 2027-06
• Study Completion: 2027-06

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Participants that have completed a prior clinical trial involving the administration of ABO-102.
• Parent(s)/legal guardian(s) of participant willing and able to complete the informed consent process and comply with study procedures and visit schedule.

Read More

Exclusion Criteria

• Planned or current participation in another clinical trial that may confound the safety and efficacy evaluation of ABO-102 during this study.
• Any other situation or medical condition that precludes the participant from undergoing procedures required in this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1	Adjuvant Immunosuppression (IS) Therapy	Participants who have completed a prior clinical trial involving the administration of ABO-102 and are able to comply with onsite scheduled visits and assessments. Select participants may receive adjuvant IS therapy.
Cohort 1	No Investigational Product	Participants who have completed a prior clinical trial involving the administration of ABO-102 and are able to comply with onsite scheduled visits and assessments. Select participants may receive adjuvant IS therapy.
Cohort 2	No Investigational Product	Participants who have completed a prior clinical trial involving the administration of ABO-102 and who cannot participate in Cohort 1. Participants will partake in a reduced number of assessments, performed either onsite or at home via a combination of telehealth and home healthcare visits.

Primary Outcome Measures

Name	Time	Method
Adverse Events	Up to Year 5	Long-term Product Safety as Defined by the Incidence, Type, and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).

Secondary Outcome Measures

Name	Time	Method
Change From Baseline (in Prior Trial) in Cerebrospinal Fluid Heparan Sulfate (CSF HS)	Up to Month 12
Change From Baseline (in Prior Trial) in the Cognitive Subtest of the Bayley Scales of Infant and Toddler Development -Third Edition (BSID-III) or the Kaufman Assessment Battery for Children - Second Edition (KABC-II), Based on Developmental Age	Baseline, Up to Year 5
Change From Baseline (in Prior Trial) in the Language Subtest of the Bayley Scales of Infant and Toddler Development -Third Edition (BSID-III) or the Kaufman Assessment Battery for Children - Second Edition (KABC-II), Based on Developmental Age	Baseline, Up to Year 5
Change From Baseline (in Prior Trial), as Assessed by the Parent Report Using the Vineland Adaptive Behavior Scale II - Survey Interview Form (VABS-II)	Baseline, Up to Year 5

Trial Locations

Locations (3)

Women's and Children's Hospital; 🇦🇺 North Adelaide, South Australia, Australia

Nationwide Children's Hospital; 🇺🇸 Columbus, Ohio, United States

Hospital Clínico Universitario de Santiago; 🇪🇸 Santiago De Compostela, Spain